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Introduction
Essential thrombocytosis (ET)is a rare condition in which the body
produces too many platelets for unknown reasons. ET can lead to
abnormal clotting and bleeding in patients. Women are 1.5 times more
likely to be affected by the condition. It also is seen more commonly in the
older population. Patients with ET can usually live a normal life if the
disease is carefully monitored and treated.
The underlying pathogenesis of essential thrombocytosis is unknown but
half of patients with the condition have a JAK2 mutation.
Diagnosis of ET is usually done after routine lab work revealing
thrombocytosis as most patients do not have symptoms of the disease.
Symptoms if present are likely secondary fatigue or problems with blood
vessels such as clotting or bleeding issues.
In most instances the thrombocytosis increases the risk of thrombosis due
to the increased platelets found in the body. There are rare cases in which
essential thrombocytosis with a severe thrombocytosis >1, 000,000/uL
causes an acquired Von Willebrand disease increasing the probable
bleeding risk. The high platelet count causes reduced VWF activity and
loss of high VWF multimers secondary to excessive binding of platelet
GP1b receptors to circulating VWF. Here we present a unique case of
essential thrombocytosis resulting in severe bilateral posterior epistaxis
requiring embolization.

Patient Imaging
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Figure 2: AP view of the left
external carotid artery showing
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Case Description
This case today is of the unexpected variety that is still undergoing
investigation and also helps educate providers on the emergent nature of
essential thrombocytosis that can be seen in some cases.
A 63 y/o male with a past medical history of recent CVA, new onset
Afib/flutter, newly diagnosed DM, HLD, and essential thrombocytosis
presented from a rehab facility to our ED with severe posterior epistaxis.
He was recently discharged to rehab 7 days prior after a lengthy 9 day
hospitalization after he suffered an acute ischemic stroke. He was started
on eliquis for stroke prevention during this hospitalization. At presentation
his vitals were stable and he had severe bilateral epistaxis requiring rhino
rocket nasal packing. The epistaxis improved initially with nasal packing.
He admitted to lightheadedness and feeling unwell when rising from
sitting. Labs were significant for Hgb of 8.8 with a platelet count of 1.4
million. His initial Hgb at presentation to the hospital was 15.8 with a
platelet count of 1.9 million. One unit of PRBC’s was ordered and the
patient was admitted to the medical ward. On hospital day 2 he again
developed severe bilateral epistaxis with profuse uncontrolled bleeding.
ENT was consulted and bilateral topical vasoconstriction was attempted
with epinephrine injection with bilateral posterior gauze packing to stop
bleeding. He continued to bleed so the patient was upgraded to the
intensive care unit and hematology and neurointerventional radiology
(Neuro IR) were consulted for further recommendations. 1 unit of fresh
frozen plasma and an additional unit of PRBC’s as well as hydroxyurea
was ordered by hematology. Neuro IR recommended bilateral
sphenopalatine artery embolization which successfully stopped bleeding
bilaterally. Our patient recovered fully without any further complications
and eliquis was restarted with plans for outpatient watchman device
placement. He was also continued on hydroxyurea after embolization as it
was found to be an effective form of lowering his platelet count over time.

Figure 3: decrease flow to the
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Discussion
Our case was unique in that our patient’s essential thrombocytosis likely
played a factor in both thrombosis( in his initial acute ischemic stroke) and
bleeding (severe epistaxis). During his episode of epistaxis his platelets
were still at 1.4 million, which is counterintuitive to the basic belief that
essential thrombocytosis increases the risk for thrombosis / clotting, not
bleeding. We suspect that the high platelet count in our patient was likely
caused by iron deficiency on top of an underlying mutation of the MPL gene.
This mutation causes thrombocytosis but does not increase the risk of
thrombosis, unlike the JAK2 mutation. Unfortunately, it is very unclear at this
time what the real underlying cause or mutation this patient has that started
all of this. We would have to do further testing on the platelets themselves
along with genetic testing to find the mutation to find all of the underlying
causes. On top of these causes there has also been literature published
showcasing an acquired Von Willebrand disease causing profuse bleeding in
patients with essential thrombocytosis. According to the literature, severe
thrombocytosis >1, 000,000/uL can cause an acquired Von Willebrand
disease through reduced VWF activity and loss of high VWF multimers. This
leads to excessive binding of platelet GP1b receptors to circulating VWF and
higher bleeding risk. Overall, there are multiple causes of bleeding in our
patient even with a platelet count of over 1.4 million. In addition to the
thrombocytosis, our patient was also started on and treated with eliquis and
aspirin for further stroke prevention from their initial hospitalization for CVA.
This most likely also contributed to the cause of their severe epistaxis. This
highlights the importance of understanding the underlying cause of essential
thrombocytosis before starting treatment and prevention on patients.
Treatment of ET varies depending on if the patient has developed
thrombosis or bleeding from high platelet count. For preventing thrombosis
aspirin can be used as a method of preventing formation of clots. Platelet
lowering medications like hydroxyurea can be used as seen in our patient.
His platelets improved significantly with hydroxyurea and iron
supplementation. Whether or not to continue on aspirin and anticoagulation
would depend on further investigation of his platelets.

Figure 5: Depicted Maxillary
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Conclusion
This case highlights the importance of understanding risks of thrombosis and
bleeding seen in patients with essential thrombocytosis along with their
underlying causes. On top of the mutations causing ineffective platelets, one
can acquire VWF disease increasing the probability of bleeding. It also
highlights a unique method of treating severe epistaxis when traditional
methods fail. There are very rare cases that require extensive intervention
such as sphenopalatine embolization.
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